The above data suggest that there is scope for a GLP-1 and GIP dual agonist combination (the so-called twincretin concept), where the former would restore euglycemia, permitting the latter to exert its full insulinotropic potential, thus synergistically improving glucose levels
Patients on semaglutide, for instance, appear to lose a higher proportion of fat relative to muscle, which means their body fat percentage drops significantly
The lack of loss in fat mass could be due to the oscillatory weight loss in SEMA group attributed to the alternate day dosing, as opposed to previous studies where SEMA was administered daily 24,25,26
Overall, I was satisfied with the ordering process
Product formulation contains no starch, no yeast, no hexane, no artificial colors or flavors
Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury